Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
Sponsor: GlaxoSmithKline
Summary
The purpose of this post-marketing commitment safety study is to evaluate the real-world safety of HZ/su vaccine during pregnancy in immunodeficient or immunosuppressed adult pregnant women between 18 and 49 years of age in the United States. The primary outcome of interest is major congenital malformations (MCMs).
Official title: Post-marketing Commitment Safety Study of HZ/su to Evaluate Pregnancy Exposures and Outcomes in Immunodeficient or Immunosuppressed Women Between 18 and 49 Years of Age
Key Details
Gender
FEMALE
Age Range
18 Years - 49 Years
Study Type
OBSERVATIONAL
Enrollment
2844
Start Date
2022-05-09
Completion Date
2028-03-31
Last Updated
2025-11-12
Healthy Volunteers
No
Conditions
Interventions
Data collection
This study will be conducted using data provided by U.S. Research Partners in the FDA's Sentinel Surveillance System. Four Research Partners will participate in this study: CVS Health Clinical Trial Services (CTS), Carelon Research, Optum and Harvard Pilgrim Health Care Institute (HPHCI).
Locations (1)
GSK Investigational Site
Canton, Massachusetts, United States